Where to buy Pharmacies address
Q & A Have questions? ask them

The effect of vitamin-mineral complex alfavit mom’s health on the levels of several vitamins and minerals in healthy women with the progression of pregnancy

Authors:Zharov EV, Serov VN
Location:Scientific Centre of Obstetrics, Gynecology, and Perinatology, Russian Academy of Medical Sciences.

The findings of last decades demonstrate that insufficient intake of vitamins, macro-and micronutrients (iron, iodine, selenium, calcium, fluoride, zinc, etc.) could lead to several diseases and complications in pregnant women (1). Specifically, it may cause disruption of fetal development and even fetal death in the I trimester, and lead to structure and function pathologies of the cardiovascular, nervous, endocrine and digestive systems at later stages (2, 6).

Moreover, today it is not possible to provide a pregnant or a feeding mother with all nutrients in recommended amounts exclusively at the expense of food (5). It is equally difficult to make a correct choice of a vitamin-mineral complex (VMC), because of their large diversity, so a vitamin-mineral complex should be chosen by a physician, taking into account the current scientific knowledge about interactions of vitamins and minerals in the field of clinical pharmacology. (2 ). In particular, it is necessary to account interactions of iron and calcium in relation to scientific evidence that the absorption of iron doubles in supplements in which iron and calcium are separated (3). Separated reception of these minerals can allow to reasonably reduce the dose of iron, without reducing the efficiency of the drug. Suggested guidelines for time-separated intake of calcium and iron (in the morning and evening) contribute to increase of bioavailability of iron in half and reduce by one-third the most common side effects such as nausea, vomiting and constipation (4).

The aim of the study was to evaluate the tolerability and clinical efficacy of vitamin-mineral complex (VMC) ALFAVIT Mom's health in healthy women with normal pregnancy.

The study included pregnant women, aged 18 to 29 years, with gestational age of 11-12 weeks, lack of chronic extragenital diseases. All participants gave informed consent. An individual intolerance to any of the VMC components and / or hyperthyroidism were chosen as exception criteria in the study.

The study followed 11 women, who, starting from 11-12 week of gestation took 1 tablet of ALFAVIT Mom's health (3 daily) with food at intervals of 4-6 hours between tablets.

Dynamic observation of the study group included five visits of physician to each pregnant women (at 11-12, 15-16, 18-20, 24-25 and 27-28 weeks) during which general clinical and special methods were employed for examination (total blood count, urinalysis, ultrasound study of the fetus). In addition, the levels of vitamin A, folic acid, copper, phosphorus and zinc in the blood serum were determined at 11-12 week and 24-25 week.

The results were recorded in “Individual card” for examination of pregnant women which received VMC ALFAVIT Mom's health.

The average age of pregnant women was 22,3 ± 3,8 years. 7 women were pregnant for the first- (63,6%), 4 for the second time36,4%) and 3 had previous births (27,3%).

Analysis of previous diseases of the surveyed participants showed (table 1) that the most frequent were diseases of the gastrointestinal tract (45,4%), varicosity (27,3%), myopia (27,3%), cystitis and/or pyelonephritis (18.2%) and vegetative dystonia (18.2%).

Table 1

Transferred extragenital diseases in pregnant women surveyed.

Extragenital diseases

Frequency of pathology (n = 11)

abs. number

%

Gastrointestinal tract: diseases

gastritis (2),

colitis (2),

Hepatitis A (1)

5

2

2

1

45,4

18,2

18,2

9,1

Varicose disease

3

27,3

Myopia

3

27,3

Acute cystitis and/or pyelonephritis

2

18,2

Vegetative dystonia

2

18,2

The participants had the following gynecological diseases in medical record(table 2): vaginitis (27.3%), menstrual irregularities (18.2%), salpingo-oophoritis (9,2%), endometritis (9.2%).

Table 2

Past gynecological diseases.

Gynecological Disease

Incidence

abs. number

%

Vaginitis

3

27,3

Menstrual irregularities

2

18,2

Adnexitis

1

9,1

Endometritis

1

9,1


This pregnancy for all women was unassisted, with no preliminary preparations, examinations or therapy, and proceeded without complications.

Analysis of the study results of vitamin A and microelements in the 11-12 and 24-25 weeks revealed (Table 3) that the vitamin A content in the blood serum of pregnant women, during intake of VMC ALFAVIT Mom's health, remained practically unchanged and was within normal limits.

Table 3

The content of vitamin A, folic acid and trace elements in healthy women with the progression of pregnancy with IUD acceptance ALFAVIT Mom's health.

Parameters

Gestation age

11-12 weeks

24-25 weeks

Vitamin A

40,7±3,8

41,6±4,7

Folic acid

18,2±9,2

23,6±17,3

Copper

0,92±0,3

1,1±0,2

Zinc

1,1±0,29

1,11±0,38

Phosphorus

0,9±0,29

1,21±0,27


The level of folic acid in 3 of 11 pregnant women at 11-12 weeks was lower than normal, which resulted in a reduction of the mean value.

During progression of pregnancy, the intake of VMC had normalized its level.

The content of copper and zinc in serum, beginning with the II trimester, was within the normal limits and there was no significant changes observed at the 24-25 week pregnancy.

The level of phosphorus in the blood serum also remained within normal limits.
Table 4 presents the results of subjective evaluation by the participating pregnant women in the study group of the effects of VMC ALFAVIT Mom's health during the II trimester.


Table 4

Subjective criteria for evaluation of the study group of pregnant women receiving VMC ALFAVIT Mom's health

Investigated parameters

Subjective assessment

Abs. number

%

Convenience:

easy

9

81,8

none

2

18,2

Overall impression:

satisfied

10

90,9

Skipping of pills:

none

9

81,8

rare (1–5)

2

18,2

often (more than 5)

0

0

Well-being:

better

9

81,8

worst

0

0

did not change

2

18,2

Would you continue to take VMC or would you switch to another preparation:

“would continue”

10

90,9

“would change”

1

9,1

Side effects:

none

11

100


Ease of use was indicated by the majority of examined participants (81.8%), 90,9% of women were satisfied with the preparation. One in five of women had reported skipping their tablets (with a frequency 1 to 5 times). The well-being during reception of the preparation improved in 4 of 5 patients, and one in five of the patients did not experience any changes. 10 out of 11 surveyed women decided to continue the reception of VMC ALFAVIT Mom's health. It is important to note that there were no side-effects reported during the therapeutical period.

No abnormalities during pregnancy were detected in surveyed women. Post-natal period proceeded without complications. There were 7 boys and 4 girls born. Apgar score was - 8,3 ± 0,11 points, weight 3501,2 ± 82,1 g, height - 49,1 ± 0,09 cm.

Thus, the daily intake of VMC ALFAVIT Mom's health could prevent the development of hypovitaminosis and microelementosis which have a major influence on pathogenesis of a number of severe complications during pregnancy and afterbirth period for mother and fetus. The separated reception of VMC components has an important effect on improvement of its efficiency by reducing the number of possible negative side-effects and maintaining the positive interactions.


Literature:

  1. Health of the Russian population and health-care facilities in 2001. Statistical materials. Zdravoohranenie, Russia. - 2003. - № 6. - P. 41-44.
  2. Korovina NA, Podzolkova NM, Zakharova IN et al. Features of nutrition in pregnant and lactating women. - M., 2004. - 64 pp.
  3. Ahn E, Pairaudeau N, Pairaudeau N. et al. A randomized cross over trial of tolerability and compliance of a micronutrient supplement with low iron separated from calcium vs. high iron combined with calcium in pregnant women. BMC Pregnancy and Childbirth. – 2006.-Р.6-10.
  4. Brooks WA, Yunus M, Santosham M, Wahed MA, Nahar K, Yeasmin S, Black RE. Zinc for severe pneumonia in very young children: double-blind placebo-controlled trial. Lancet, 2004.- V. 363 (9422).- P. 1683.
  5. Yajnik C. Nutritional control of fetal growth. Nutr Rev. 2006.- Р.236-238.